



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. AM100123)

In re Patent Application of:)	Appln. No.: 09/840,485
)	Confirmation No.: 5730
ROCKY B. BIGBIE <i>et al.</i>)	Customer No.: 25291
)	Group Art Unit: 1645
Filed: 04/23/2001)	Examiner: Virginia Allen Portner
)	
For: EQUINE PROTOZOAL)	
MYELOENCEPHALITIS VACCINE)	

AMENDMENT

Dear Sir:

Responsive to the Office communication mailed June 21, 2005 in the above-referenced patent application, please amend the above-referenced application using the below instructions.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

In accord with 37 C.F.R. § 1.121, the amendment to the claims and a complete listing of all pending claims in the application begin on a separate sheet. The amendment adds no new matter into the application. Most of the revisions merely rephrase or reword the claims where the same meaning remains intact. The changes that involve the "plasmid" DNA in Claims 1-3, 8, 9 and 15 find support in the application on page 7, lines 11-14 thereof; and the correction of "dosage unit form" in Claims 4, 6 and 7 finds support in the application on page 10, lines 20-23 thereof. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto.

Applicants gratefully acknowledge that the Examiner has kindly withdrawn several of the previous rejections of record as set forth on page 3 of the Office action.

It is also gratefully noted that the Examiner has rejoined the antibody-inducing derived antigens from *S. neurona* inactivated cells with the subject matter that had been elected as a consequence of the restriction requirement made by the previous examiner. In order for the new Examiner to appreciate the invention described in the application as a whole, the present amendment has rewritten all of the product and method claims for the better readability thereof.

Page 1 of 15